Studies of preclinical Alzheimer disease (AD) have unexpectedly shown amyloid-β deposition and/or AD-like neurodegenerative changes in the brains of a high proportion of clinically normal elderly individuals. As two recent reports illustrate, imaging and fluid biomarker studies in these individuals are yielding new insights into the pathophysiology of cognitive ageing.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Journal of Neuroinflammation Open Access 07 July 2020
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Gordon, B. A. et al. Longitudinal β-amyloid deposition and hippocampal volume in preclinical Alzheimer disease and suspected non-Alzheimer disease pathophysiology. JAMA Neurol. http://dx.doi.org/10.1001/jamaneurol.2016.2642 (2016).
Mormino, E. C. et al. Heterogeneity in suspected non-Alzheimer disease pathophysiology among clinically normal older individuals. JAMA Neurol. http://dx.doi.org/10.1001/jamaneurol.2016.2237 (2016).
Jack, C. R. Jr et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119–128 (2010).
Sperling, R. A. et al. Towards defining the preclinical stage of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association Workgroup. Alzheimers Dement. 7, 280–292 (2011).
Jack, C. R. Jr et al. An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease. Ann. Neurol. 71, 765–775 (2012).
Jack, C. R. Jr et al. Suspected non-Alzheimer disease pathophysiology — concept and controversy. Nat. Rev. Neurol. 12, 117–124 (2016).
Johnson, K. A. et al. Tau positron emission tomographic imaging in aging and early Alzheimer's disease. Ann. Neurol. 79, 110–119 (2016).
Mormino, E. C. et al. Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 71, 1379–1385 (2014).
Burnham, S. C. et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. Lancet Neurol. 15, 1044–1053 (2016).
Boche, D., Denham, N., Holmes, C. & Nicoll, J. A. Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol. 120, 369–384 (2010).
The author gratefully acknowledges research supported from the NIH (grants P50 AG16574, U01 AG06786 R01 AG11378 and R01 AG41851), and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program of the Mayo Foundation.
The author serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study, and is an investigator in clinical trials sponsored by Biogen, TauRX Pharmaceuticals, Lilly Pharmaceuticals and the Alzheimer's Disease Treatment and Research Institute, University of Southern California.
About this article
Cite this article
Knopman, D. Preclinical Alzheimer disease — the new frontier. Nat Rev Neurol 12, 620–621 (2016). https://doi.org/10.1038/nrneurol.2016.153
This article is cited by
Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer’s disease and supporting differential diagnosis
Annals of Nuclear Medicine (2021)
Journal of Neuroinflammation (2020)
Recent advances in the design and applications of amyloid-β peptide aggregation inhibitors for Alzheimer’s disease therapy
Biophysical Reviews (2019)